Displaying all 2 publications

Abstract:
Sort:
  1. Liquid biopsies and exosomal ncRNA: Transforming pancreatic cancer diagnostics and therapeutics
    Balaraman AK, Moglad E, Afzal M, Babu M, Goyal K, Roopashree R, et al.
    Clin Chim Acta, 2024 Dec 18.
    PMID: 39706249 DOI: 10.1016/j.cca.2024.120105
    Pancreatic cancer is a highly fatal malignancy due to poor early detection rate and resistance to conventional therapies. This review examines the potential for liquid biopsy as a transformative technology to identify diagnostic and therapeutic targets in pancreatic cancer. Specifically, we explore emerging biomarkers such as exosomal non-coding RNAs (ncRNAs), circulating tumor DNA (ctDNA), and circulating tumor cells (CTCs). Tumor-derived exosomes contain nucleic acid and protein that reflect the unique molecular landscape of the malignancy and can serve as an alternative diagnostic approach vs traditional biomarkers like CA19-9. Herein we highlight exosomal miRNAs, lncRNAs, and other ncRNAs alongside ctDNA and CTC-based strategies, evaluating their combined ability to improve early detection, disease monitoring and treatment response. Furthermore, the therapeutic implications of ncRNAs such as lncRNA UCA1 and miR-3960 in chemoresistance and progression are also discussed via suppression of EZH2 and PTEN/AKT pathways. Emerging therapeutic strategies that target the immune response, epithelial-mesenchymal transition (EMT) and drug resistance are explored. This review demonstrates a paradigm shift in pancreatic cancer management toward personalized, less invasive and more effective approaches.
  2. Prostate cancer burden in South Asia: A systematic analysis of global burden of disease data (1990-2021)
    Kumar V, Jena D, Zahiruddin QS, Roopashree R, Kaur M, Srivastava M, et al.
    Int J Urol, 2024 Dec 13.
    PMID: 39670291 DOI: 10.1111/iju.15641
    OBJECTIVES: The objectives of this study were to analyze trends in prostate cancer incidence, incidence, mortality, and disability-adjusted life years (DALYs) from 1990 to 2021 via data from the Global Burden of Disease (GBD) study in South Asia. Additionally, the study projects future prostate cancer incidence rates up to 2031 to inform public health interventions in South Asia.

    METHODS: Data covering South Asian countries such as Bangladesh, Bhutan, India, Nepal, and Pakistan were obtained from the GBD 2021 portal. Age-standardized rates (ASRs) for prostate cancer metrics, including incidence (ASIR), prevalence (ASPR), mortality (ASMR), and DALYs (ASDR), were analyzed via joinpoint and ARIMA modeling techniques. Geographic variations in ASRs were mapped via QGIS software.

    RESULTS: The prostate cancer ASIR, ASPR, and ASDR significantly increased from 1990 to 2021, particularly among individuals aged 60-65 years. The highest incidence and mortality rates were observed in Pakistan. The total percentage change in incidence in India was the highest at 61%. Projections indicate a continued rise in prostate cancer incidence, with South Asia's ASIR expected to reach 9.34 per 100 000 by 2031.

    CONCLUSIONS: The growing burden of prostate cancer in South Asia highlights the need for enhanced screening programs, public awareness, and healthcare infrastructure improvements. Without intervention, the increasing incidence and mortality rates could strain healthcare resources, emphasizing the urgency of region-specific public health strategies.

Related Terms
    Try searching for something
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links